Recent advance in mechanism of cognitive impairment patients with comorbid metabolic syndrome through PI3K/Akt signaling pathway
10.3760/cma.j.cn115354-20210603-00354
- VernacularTitle:代谢综合征通过PI3K/Akt信号通路损伤认知功能的机制研究进展
- Author:
Bozhen NIU
1
;
Xiangyu ZHANG
;
Yang XU
;
Kai TIAN
;
Chunyan FENG
Author Information
1. 天津中医药大学第一附属医院康复科（国家中医针灸临床医学研究中心），天津 300193
- Keywords:
Metabolic syndrome;
Cognitive function impairment;
Phosphatidylinosito-3 kinase/protein kinase B signaling pathway
- From:
Chinese Journal of Neuromedicine
2022;21(1):92-95
- CountryChina
- Language:Chinese
-
Abstract:
Multiple studies has indicated an increased risk of cognitive decline in patients with metabolic syndrome (MetS), and treatments targeting the abnormal metabolic components of MetS are considered to be able to prevent and delay the onset of dementia. Phosphatidylinosito-3 kinase/protein kinase B (PI3K/Akt) signaling pathway plays an important role in peripheral metabolism and brain biological function, and is a common signaling pathway in the pathogenesis of MetS and cognitive impairment. PI3K/Akt signaling pathway has been attempted to use as an entry point for treatment of cognitive impairment related with MetS. In our research, the mechanism of cognitive impairment in MetS through PI3K/Akt signaling pathway is reviewed from aspects of glucose uptake, cholesterol synthesis, acetylcholine level, Aβ aggregation and tau protein phosphorylation in brain, which aims to clarify how PI3K/Akt signaling pathway participates in cognitive impairment related to comorbid MetS, and to find new targets for treating cognitive impairment related to comorbid MetS.
